The FDA’s database for drug approvals includes an Abbreviated New Drug Application (ANDA) numbered ANDA083639 submitted by Roche. The application covers the brand name ENDEP, an oral tablet formulation of amitriptyline hydrochloride.
The ANDA lists five product variants, each with a distinct strength—10 mg, 25 mg, 50 mg, 75 mg, and 100 mg. All five tablets are designated as “Discontinued” in marketing status, indicating they are no longer marketed.
Actualizaciones regulatorias25 ago 2026•1 min de lectura
FDA Lists ENDEP Amitriptyline Tablet Products (ANDA083639)
FDA’s ANDA083639 lists five ENDEP oral amitriptyline tablets (10‑100 mg) from Roche, all marked discontinued.
Recopilado por el equipo de PharmaCountry · Fuente: FDA.gov
Calificaciones
(0)
(0)
(0)
(0)
(0)
Más artículos
Ver todos los artículosInvestigación e Informes
Global Finished Dosage Manufacturing Landscape 2026
5 oct 2026
Actualizaciones regulatoriasKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28 sept 2026
AnálisisPharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28 sept 2026
Deja tu valoración